5 Key Takeaways

• 1

  The FDA approved insulin efsitora alfa-gobe (Onswik) as a once-weekly basal insulin for adults with type 2 diabetes.

• 2

  The approval was based on the QWINT phase 3 clinical development program involving over 3,400 adults with type 2 diabetes.

• 3

  Insulin efsitora alfa-gobe met the primary endpoint of noninferiority for hemoglobin A1c reduction compared to daily insulin comparators.

• 4

  Common adverse reactions include hypoglycemia, allergic reactions, and injection-site reactions, among others.

• 5

  Insulin efsitora alfa-gobe is contraindicated in patients with type 1 diabetes due to the risk of severe hypoglycemia.